ClinicalTrials.gg

Program

KPC000154

A development code. Also written as “KPC000154 10mg Tablet Intervention”, “KPC000154 30mg Tablet Intervention” and “KPC000154 60mg Tablet Intervention”.

Its studies are led by Kunming Pharmaceuticals.

Furthest: phase 1, since Feb 27, 20251 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kunming Pharmaceuticals11 open or runningphase 1since Feb 27, 2025Feb 27, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 27, 2025First study: phase 1 study in Healthy Subjects、Lipid MetabolismFirst studyNCT06867406 · 92 planned · China

TargetBeta

THRB →read by rule
“KPC000154 is a thyroid hormone receptor beta (THR-β) agonist that improves NASH by increasing hepatic fat metabolism and reducing fat toxicity.”study text, by rule · the study

Other programs on THRB

ProgramCompanyFurthest phaseStudies
resmetiromruleMadrigal Pharmaceuticalsphase 422
KYLO-0603Sino Biopharmaceuticalphase 22
CG-0416rulehongkong-curegene-innovation-co-limitedphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06867406Healthy Subjects、Lipid Metabolism · China1Not yet recruitingNov 30, 202592

How it is read

Names in the registry

  • “KPC000154 10mg Tablet Intervention”, 1 entry
  • “KPC000154 30mg Tablet Intervention”, 1 entry
  • “KPC000154 60mg Tablet Intervention”, 1 entry
  • “KPC000154 120mg Tablet Intervention”, 1 entry
  • “KPC000154 200mg Tablet Intervention”, 1 entry

Codes read as this program: KPC000154.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.